Actualités MedMira Inc - MIR | Actions TSX Venture Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

MedMira Strengthens and Expands Board

HALIFAX, Nova Scotia, July 14, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces...

MedMira Reports Third Quarter Results FY2022

HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on...

MedMira Receives Patent for its Unique Quantitative Diagnostic System

HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces...

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an...

VYRA™ Product Line Update

HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an...

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces...

MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) launches...

MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

HALIFAX, Nova Scotia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) has...

MedMira Provides a Pre-Annual General Meeting Update

HALIFAX, Nova Scotia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a...

MedMira Reports First Quarter Results FY2022

HALIFAX, Nova Scotia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on...

MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

HALIFAX, Nova Scotia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces...

MedMira strengthen its Board with New Appointment

HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced...

MedMira announces significant debt reduction and additional growth capital

HALIFAX, Nova Scotia, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces a...

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

HALIFAX, Nova Scotia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on...

MedMira Closes New Equity Investment for Future Growth

HALIFAX, Nova Scotia, July 14, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) has closed...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MedMira Inc (MIR)

Outils de qualité professionnelle, pour des investisseurs individuels.

MIR Actualités

MedMira Strengthens and Expands Board

MedMira Reports Third Quarter Results FY2022

MedMira Receives Patent for its Unique Quantitative Diagnostic System

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

VYRA™ Product Line Update

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

MedMira Provides a Pre-Annual General Meeting Update

MedMira Reports First Quarter Results FY2022

MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

MedMira strengthen its Board with New Appointment

MedMira announces significant debt reduction and additional growth capital

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

MedMira Closes New Equity Investment for Future Growth

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

MedMira Inc (MIR) Actualités

MedMira Inc (MIR)

Outils de qualité professionnelle, pour des investisseurs individuels.

MIR Actualités

MedMira Strengthens and Expands Board

MedMira Reports Third Quarter Results FY2022

MedMira Receives Patent for its Unique Quantitative Diagnostic System

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

VYRA™ Product Line Update

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

MedMira Provides a Pre-Annual General Meeting Update

MedMira Reports First Quarter Results FY2022

MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

MedMira strengthen its Board with New Appointment

MedMira announces significant debt reduction and additional growth capital

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

MedMira Closes New Equity Investment for Future Growth

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres